---
search:
  boost: 2 
---

# Inhaled

This is a subcategory of Infectious Disease Agents.

## Formulary

### Preferred

| Preferred                   | Generic Name                               |         Quantity          |        Time (Days)        |
| :-------------------------- | :----------------------------------------- | :-----------------------: | :-----------------------: |
| Tobramycin <sup>PA QL</sup> | Tobramycin Nebulizing Soln (all strengths) | Determined pursuant to PA | Determined pursuant to PA |

### Non-Preferred

| Non-Preferred                | Generic Name                               |         Quantity          |        Time (Days)        |
| :--------------------------- | :----------------------------------------- | :-----------------------: | :-----------------------: |
| Arikayce                     |                                            |                           |                           |
| Bethkis <sup> QL</sup>       | Tobramycin Nebulizing Soln (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Cayston                      |                                            |                           |                           |
| Kitabis Pak <sup> QL</sup>   |                                            |                           |                           |
| Tobi Podhaler <sup> QL</sup> |                                            |                           |                           |

## Length of Authorizations

28 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria

- Must provide documentation of cultures demonstrating drug is prescribed in alignment with approved indication

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **28 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., culture conversion, symptom improvement)

**QL** - Tobramycin drugs: 56 doses in 56 days

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=76)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=26)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
